bpc-157 pharmacokinetics oral bioavailability as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Oral bioavailability – An ABC
Description
A 2023 safety review ( Clinical, Cosmetic and Investigational Dermatology ) analyzed 12 studies (n=512): most common adverse events were transient erythema (4.2%) and pruritus (2.8%)
Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age
While Tom20 and Tom22 bind the amino-terminal presequences, Tom70 binds the internal signals to prevent aggregation of the preproteins
However, long-term human safety trials are lacking, so usage should be approached with caution
Physical signs
